Adverse events reported by adults with major depressive disorder receiving transdermal selegiline or placebo

Major adverse eventsSelegiline % (n=89)Placebo % (n=88)
Note: All p>0.05, except application site reactions (p=0.006).
Any adverse event87.678.4
Cardiovascular event3.46.8
Nervous event28.131.8
Digestive events25.829.5
Respiratory events15.718.2
Urogenital events13.511.4
Musculoskeletal events4.58.0
Other events44.940.9
Application site reaction36.017.0